Department of Psychiatry, University of Münster, Münster, Germany.
Neuropsychobiology. 2010;62(2):121-31. doi: 10.1159/000317285. Epub 2010 Jun 30.
BACKGROUND/AIMS: The norepinephrine transporter (NET) and serotonin transporter (5-HTT) genes constitute promising candidate genes in major depression. Seven polymorphisms in the promoter, intronic and exonic region of the NET gene, as well as serotonin-transporter-linked promoter region (5-HTTLPR) and 5-HTT rs25531 polymorphisms were analyzed with respect to antidepressant treatment response with particular attention to gender effects and subtypes of melancholic or anxious depression.
252 unrelated Caucasian patients (f = 142; m = 110) with major depression were genotyped for NET and 5-HTT polymorphisms. Genotype effects on Hamilton Depression Rating Scale score changes over 6 weeks of antidepressant treatment were analyzed using analysis of covariance with repeated measures.
There was no effect of any of the 7 investigated NET, or the two 5-HTT polymorphisms, on the overall treatment response. An additional -/CT insertion/deletion (ins/del) polymorphism (rs58532686), however, was significantly associated with melancholic depression, with a better response in 12 patients carrying the deletion. Stratification for anxious versus nonanxious depression revealed a significantly detrimental effect of the less active 5-HTTLPR S allele (p = 0.007) and 5-HTTLPR/5-HTT rs25531 haplotypes on treatment response in patients with anxious depression.
The present findings do not support a major impact of the NET and 5-HTT genes on antidepressant treatment response in major depression per se. However, there might be an impact of a -/CT ins/del polymorphism in the enhancer domain of the NET gene on treatment response in melancholic depression, which remains to be functionally investigated in future studies. The observed significant influence of the 5-HTT gene variation on antidepressant treatment in anxious depression points to anxious depression as a potential diagnostic entity of its own, requiring specific diagnostic and therapeutic attention.
背景/目的:去甲肾上腺素转运体(NET)和 5-羟色胺转运体(5-HTT)基因是重度抑郁症的潜在候选基因。本研究分析了 NET 基因启动子、内含子和外显子区域的 7 个多态性,以及 5-HTT 基因的色氨酸相关联启动子区(5-HTTLPR)和 5-HTT rs25531 多态性,以特别关注性别效应和忧郁或焦虑性抑郁的亚型,分析它们对抗抑郁治疗反应的影响。
对 252 例无关的白种人重度抑郁症患者(女性 142 例,男性 110 例)进行 NET 和 5-HTT 多态性基因分型。采用重复测量协方差分析,分析 Hamilton 抑郁量表评分在 6 周抗抑郁治疗期间的变化与基因型之间的关系。
未发现所研究的 7 个 NET 多态性或 5-HTT 的两种多态性与整体治疗反应有关。然而,一个额外的-/CT 插入/缺失(ins/del)多态性(rs58532686)与忧郁性抑郁症显著相关,携带缺失的 12 例患者反应更好。对焦虑性与非焦虑性抑郁症进行分层,发现不太活跃的 5-HTTLPR S 等位基因(p = 0.007)和 5-HTTLPR/5-HTT rs25531 单体型对焦虑性抑郁症患者的治疗反应有显著的不利影响。
本研究结果不支持 NET 和 5-HTT 基因对重度抑郁症抗抑郁治疗反应有重大影响。然而,NET 基因增强子区域的-/CT ins/del 多态性可能对忧郁性抑郁症的治疗反应有影响,这有待于进一步的功能研究。观察到 5-HTT 基因变异对焦虑性抑郁症抗抑郁治疗的显著影响表明,焦虑性抑郁症可能是一种独立的潜在诊断实体,需要给予特定的诊断和治疗关注。